Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
UNCY vs CNTB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
UNCY Captures Overall Composite Edge (43.7 HOLD vs 41.0 SELL), While CNTB Leads 4–1 on Growth & Valuation Pillars
UNCY Overall Winner
6-Pillar Tally: UNCY 1 – 4 CNTB (1 Tie)
Matrix Metrics: UNCY 6 – 3 CNTB
As of Nov 17, 2026, Unicycive Therapeutics, Inc. (UNCY) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (43.7/100 HOLD vs. 41.0/100 SELL) after splitting the core matrix 6–3 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. UNCY trades at $3.74 (2.5x Forward P/E, 0.0% operating margin) versus CNTB at $0.59 (0.8x Forward P/E, -2384.5% operating margin).
- Growth vs. Quality Trade-Off: UNCY earns the overall head-to-head edge with a stronger Unified Composite Score (43.7/100 HOLD vs. CNTB 41.0/100 SELL) and 1.02β · 65% Vol risk profile, whereas CNTB leads top-line expansion (+5666.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: UNCY is currently in a Breakdown options structure phase (RSI 47.6); meanwhile CNTB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About UNCY vs CNTB
UNCY
Head-to-Head Winner
Unicycive Therapeutics, Inc. Common Stock
$3.74
+1.08% 1D
Market Cap
$97.2M
TTM Revenue
N/A
Forward P/E
2.5x
Beta / 30D Vol
1.02β · 65% Vol
Unified Composite Score
43.7
HOLD
Tech 30.0
Fund 50.0
Flow 70.0
Mom 58.9
Weinstein Technical Phase
Neutral · Hold
CNTB
Connect Biopharma Holdings Limited Ordinary Shares
$0.59
-7.94% 1D
Market Cap
$42.6M
TTM Revenue
$3.0M
Forward P/E
0.8x
Beta / 30D Vol
0.92β · 68% Vol
Unified Composite Score
41.0
SELL
Tech 25.0
Fund 48.0
Flow 66.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (UNCY 1 – 4 CNTB)
1. Valuation Multiples
CNTB
Forward P/E
2.5x
0.8x
Trailing P/E
2.0x
0.8x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
5.5x
2. Growth & Scale
CNTB
Revenue Growth (YoY)
+0.0%
+5666.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$3.0M
Market Cap
$97.2M
$42.6M
3. Profitability & Quality
UNCY
Gross Margin
N/A
100.0%
Operating Margin
0.0%
-2384.5%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-101.1%
-140.5%
4. Balance Sheet & Cash Flow
CNTB
Cash Generation (TTM)
-$28M
-$61M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$43M Net Cash
$26M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CNTB
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
79.1% (30th %ile)
397.3% (100th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: UNCY (6) vs CNTB (3)| Institutional Metric | UNCY | CNTB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $97.2M | $42.6M | UNCY | |
| Trailing P/E Ratio | 2.0x | 0.8x | CNTB | |
| Forward P/E Ratio | 2.5x | 0.8x | CNTB | |
| Revenue Growth (YoY) | +0.0% | +5666.7% | CNTB | |
| Operating Margin (TTM) | 0.0% | -2384.5% | UNCY | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -101.1% | -140.5% | UNCY | |
| 52-Week Range Position | 8% ($3–$9) | 1% ($1–$4) | UNCY | |
| Beta / 30D Volatility | 1.02β · 65% Vol | 0.92β · 68% Vol | UNCY | |
| Unified Institutional Score | 43.7 / 100 (HOLD) | 41.0 / 100 (SELL) | UNCY | |
| Trailing 12M Revenue (USD) | N/A | $3.0M | Scale | |
| Gross Profit Margin (TTM) | N/A | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 5.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$28M ($43M Net Cash) | -$61M ($26M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
UNCY +40.77 pp
3M Horizon
UNCY +42.97 pp
6M Horizon
UNCY +21.35 pp
1Y Horizon
UNCY +38.04 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | UNCY Revenue | CNTB Revenue | UNCY Op. Margin | CNTB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2022 | $0M | N/A | -1898.2% | N/A | UNCY |
| FY2023 | $0M | N/A | -3077.6% | N/A | UNCY |
| FY2024 | N/A | $30M | N/A | -86.2% | CNTB |
| FY2025 | N/A | $0M | N/A | -90740.6% | CNTB |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
UNCY
BREAKDOWN
Current IV
79.1%
IV Percentile
30th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact UNCY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CNTB
UNCLASSIFIED
Current IV
397.3%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CNTB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
UNCY Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CNTB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ UNCY vs CNTB Key Questions & Quantitative Answers
As of Nov 17, 2026, Unicycive Therapeutics, Inc. (UNCY) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (43.7/100 HOLD vs. 41.0/100 SELL) after splitting the core matrix 6–3 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. UNCY trades at $3.74 (2.5x Forward P/E, 0.0% operating margin) versus CNTB at $0.59 (0.8x Forward P/E, -2384.5% operating margin). Growth vs. Quality Trade-Off: UNCY earns the overall head-to-head edge with a stronger Unified Composite Score (43.7/100 HOLD vs. CNTB 41.0/100 SELL) and 1.02β · 65% Vol risk profile, whereas CNTB leads top-line expansion (+5666.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: UNCY is currently in a Breakdown options structure phase (RSI 47.6); meanwhile CNTB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CNTB leads the Growth & Scale pillar: UNCY posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CNTB at +5666.7% YoY revenue growth and +0.0% YoY earnings growth on $3.0M TTM revenue (100.0% gross margin, -2384.5% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), UNCY cumulative revenue shifted N/A while CNTB shifted N/A. In operating R&D and SG&A reinvestment, UNCY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CNTB.
CNTB screens cheaper on headline valuation multiples. UNCY trades at 2.5x Forward P/E, 2.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CNTB trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UNCY (-101.1% ROE) versus CNTB (-140.5% ROE) capital efficiency.
In options market volatility and institutional positioning, UNCY carries 79.1% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.02β · 65% Vol realized risk). By comparison, CNTB carries 397.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 68% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CNTB vs UNCY · Reverse Pair
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal